ArticlePharmaceutical medicine2021
Preparing for the Next Normal: Transformation in the Role of Medical Affairs Following the COVID-19 Pandemic.
Article in Pharmaceutical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Embracing Digital as a Paradigm Shift in Medical Affairs.Pharmaceutical medicine · 2026Review
- Transformation of a Medical Information Department to Meet the New Healthcare Realities of the Post-Pandemic Era.Pharmaceutical medicine · 2026Article
- Understanding the National Healthcare Ecosystem to Position Medical Affairs as a Strategic Element: Lessons Learned from AstraZeneca Spain.Pharmaceutical medicine · 2025Article
- The Evolution of In-Field Medical Affairs: Introducing the Strategic Scientific Advisor.Pharmaceutical medicine · 2025Article
- Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs.Pharmaceutical medicine · 2024Article
- Considerations for Effective Communication of Medical Information.Pharmaceutical medicine · 2023Article
- Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core.Pharmaceutical medicine · 2022Article
- Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond.Pharmaceutical medicine · 2022Review
- Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians.Frontiers in pharmacology · 2022Article
- To Tweet or Not to Tweet: A Longitudinal Analysis of Social Media Use by Global Diabetes Researchers.Pharmaceutical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The medical affairs function represents one of the scientific interfaces in a pharmaceutical organization. Over the last two decades, medical affairs has evolved from being a support function to a strategic pillar within organizational business units. The COVID-19 pandemic has given rise to unforeseen circumstances resulting in a dramatic change in external stakeholder engagements, catapulting the medical affairs function into leading the way on scientific engagements and patient-centric endeavors. The changes in stakeholder interactions and behavior as a result of the pandemic last year are likely to persist in the foreseeable future for which medical affairs professionals need to enhance existing skill sets and acquire expertise in newer domains. In this paper, the transformation of the medical affairs team to a key strategic partner and the skills required to strengthen this transition, in the next normal of a post-COVID world, is explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.